[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370215-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370215-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","discussion-on-the-mechanism-of-her2-resistance-in-esophagogastric-junction-and-gastric-cancer-in-the-era-of-immunotherapy","Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy","","HER2 is a critical biomarker and therapeutic target in gastric and gastroesophageal junction (G/GEJ) cancers, yet resistance limits durable benefit from HER2-targeted agents such as trastuzumab. This review summarizes key resistance mechanisms in HER2-positive G/GEJ cancer, including alterations in the HER2 receptor (mutations and expression changes), dysregulated downstream signaling, and interactions with the tumor microenvironment (TME). It also evaluates emerging strategies, including antibody-drug conjugates (ADCs) and combination therapies, aiming to support improved treatment development for resistant patients.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/discussion-on-the-mechanism-of-her2-resistance-in-esophagogastric-junction-and-gastric-cancer-in-the-era-of-immunotherapy/370215/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/discussion-on-the-mechanism-of-her2-resistance-in-esophagogastric-junction-and-gastric-cancer-in-the-era-of-immunotherapy/370215.png","ImageObject",300,407,{"name":42,"@type":43},"Olivia Brown","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does HER2 play in gastric and G/GEJ cancers?","Question",{"text":63,"@type":64},"HER2 functions as a transmembrane tyrosine kinase that activates downstream signaling via pathways such as Ras/MAPK and PI3K/Akt, supporting proliferation and survival. Its amplification or overexpression can contribute to cancer development and progression, with distinct behavior in gastric/G/GEJ tumors.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is HER2 status determined in gastric cancer?",{"text":68,"@type":64},"HER2 testing commonly uses immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The reviewed guidance notes that strongly positive or clearly negative IHC can avoid additional FISH in certain cases, while equivocal IHC requires confirmatory FISH. Positivity is based on defined HER2/CEP17 ratio or copy number thresholds.",{"name":70,"@type":61,"acceptedAnswer":71},"Why does resistance to HER2-targeted therapy develop?",{"text":72,"@type":64},"Resistance arises through multiple mechanisms, including HER2 receptor alterations (mutations and expression level changes), changes in downstream signaling pathways, and effects from the tumor microenvironment (TME). These processes can undermine long-term effectiveness of HER2-targeted treatments.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370215,1790418769,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},16904993612988,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","REVIEW  \nDiscussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy  \nYan Zhanga,b, Wenxuan Fana,c, Fei Sua,c, Xiaoling Zhanga, Yunyi Dua, Weiling Lia,b, Yangjun Gaoa, Wenqing Hud, and Jun Zhao a  \naDepartment of Oncology, Changzhi People’s Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China; bGraduate School, Changzhi Medical College, Changzhi, Shanxi, China; cGraduate School, Shanxi Medical University, Taiyuan, Shanxi, China; dDepartment of Gastrointestinal Surgery, Changzhi People’s Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, China  \nABSTRACT  \nHuman epidermal growth factor receptor 2 (HER2) is a critical biomarker and therapeutic target in gastric/ gastroesophageal junction (G/GEJ) cancers, despite the initial success of HER2-targeted therapies, such astrastuzumab, resistance to these drugs has emerged as a major impediment to effective long-term treatment. This review examines the mechanisms of drug resistance in HER2-positive G/GEJ cancer, the primary mechanisms of resistance explored include alterations in the HER2 receptor itself, such as mutations and changes in expression levels, as well as downstream signaling pathways, and interactions with the tumor microenvironment (TME) . Furthermore, the review discusses the Novel therapeutic approaches, including the use of antibody-drug conjugates (ADCs) and combination therapies are assessed for their potential to enhance outcomes. By integrating recent research findings and clinical trials, this review aims to provide oncologists and researchers with insights into developing more effective treatments for patients with drug-resistant HER2-positive G/GEJ cancer.  \nARTICLE HISTORY  \nReceived 6 November 2024 Revised 11 January 2025 Accepted 24 January 2025  \nKEYWORDS  \nHER2-positive; gastric cancer; gastroesophageal junction cancer; drug resistance; HER2 receptor  \nIntroduction  \nHuman epidermal growth factor receptor 2 (HER2) is a member of the epidermal growth factor receptor (EGFR) family and encodes a transmembrane protein with tyrosine kinase activity. Its structure includes an extracellular domain, a transmembrane domain, and an intracellular tyrosine kinase domain. The EGFR family comprises HER1, HER2, HER3, and HER4, which share structural similarities. HER2 mediates signal transduction through heterodimerization with other family members and tyrosine kinase autophosphorylation. This process primarily influences cell proliferation, differentiation, apoptosis, and other cellular processes via the Ras/MAPK and PI3K/Akt signaling pathways. 1 When HER2 protein is overexpressed or gene amplification occurs, it leads to excessive activation of downstream signaling pathways, resulting in uncontrolled cell proliferation. This is closely associated with the development and progression of various cancers, including breast cancer, gastric cancer, lung cancer, colorectal cancer, and bladder cancer. While HER2 is a broadly applicable concept, its role and therapeutic implications can vary significantly across different tumor types due to variations in tumor biology, microenvironment, and HER2 expression patterns. Gastric and GE Junction adenocarcinomas exhibit distinct HER2-related characteristics compared to other cancers, such as breast cancer, which necessitate a tailored approach to understanding and targeting HER2 in this context. Additionally, HER2 positive tumors exhibit distinct biological behaviors compared to HER2 negative tumors. For instance,  \nHER2 positive gastric cancer tends to be more invasive and may have a poorer prognosis.2 This has made HER2 positive gastric cancer a key focus of research, and a series of targeted therapy studies have been conducted specifically for HER2 positive gastric cancer.  \nGastric cancer (GC) ranks fifth in global cancer incidence and fourth in mortality rates.3 Despite a recent decline in incidence and mortality, treatment outcomes","cbCaijtBw7L47uTx","https://ap.wps.com/l/cbCaijtBw7L47uTx","pdf",2029648,14,"English","# Introduction\n## HER2 biology and signaling in cancer\n## HER2 assessment in gastric and G/GEJ adenocarcinoma\n## Treatment landscape and relevance of resistance","[{\"question\":\"What role does HER2 play in gastric and G/GEJ cancers?\",\"answer\":\"HER2 functions as a transmembrane tyrosine kinase that activates downstream signaling via pathways such as Ras/MAPK and PI3K/Akt, supporting proliferation and survival. Its amplification or overexpression can contribute to cancer development and progression, with distinct behavior in gastric/G/GEJ tumors.\"},{\"question\":\"How is HER2 status determined in gastric cancer?\",\"answer\":\"HER2 testing commonly uses immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). The reviewed guidance notes that strongly positive or clearly negative IHC can avoid additional FISH in certain cases, while equivocal IHC requires confirmatory FISH. Positivity is based on defined HER2/CEP17 ratio or copy number thresholds.\"},{\"question\":\"Why does resistance to HER2-targeted therapy develop?\",\"answer\":\"Resistance arises through multiple mechanisms, including HER2 receptor alterations (mutations and expression level changes), changes in downstream signaling pathways, and effects from the tumor microenvironment (TME). These processes can undermine long-term effectiveness of HER2-targeted treatments.\"}]","Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy | PDF",1790187382,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fb7e7212c1f4f1b73b19713b7cc879c6.webp",983,1280,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c392bb576b069aac9cbb6b9c416c0120.webp",982,1278,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f4a9b16b13c8718850e34736bd1f21b.webp",981,1277,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f30312f606d212873bd92c34b400da9e.webp",980,1276]